Biotech News
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
ir.tgtherapeutics.com2026-05-06 14:45 EST
Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of approximately $875-900 million in total global revenue for 2026 Conference call to be held today,